Ke‐Neng Chen

6.8k citations
104 papers · 4.1k · 5 hit papers · h-index 30

Impact in

    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Gastric Cancer Management and Outcomes
  • Oncology top 2%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies

Papers in

Ke‐Neng Chen

102 papers receiving 4.0k citations

Ke‐Neng Chen's Hit Papers

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial 2024 · 137 citations
1370+3+6Years since publication200400600

Peers

Ke‐Neng Chen
Comparison fields: 5 of 89
  • Pulmonary and Respiratory Medicine 1.9k
  • Oncology 1.2k
  • Cancer Research 458
  • Neurology 368
  • Surgery 641
Replace Tobias Raphael Overbeck with:
Tobias Raphael Overbeck Germany
Miso Kim South Korea
Federica Bertolini Italy
Roberto Bordonaro Italy
Pierre Ruffiè France
Flavio G. Rocha United States
Dirk Klingbiel Switzerland
Claudia Proto Italy
Shugeng Gao China
Monia Ouali France
Ke‐Neng Chen relative to Tobias Raphael Overbeck Germany Tobias Raphael Overbeck's profile →
Citations per field
00.5×2×4×6.4×
Tobias Raphael Overbeck · 1×
Citations per year

Countries citing papers authored by Ke‐Neng Chen

Since Specialization
Citations

This map shows the geographic impact of Ke‐Neng Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke‐Neng Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke‐Neng Chen more than expected).

Fields of papers citing papers by Ke‐Neng Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ke‐Neng Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke‐Neng Chen. The network helps show where Ke‐Neng Chen may publish in the future.

Co-authors

The 25 scholars most cited alongside Ke‐Neng Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ke‐Neng Chen Line = papers co-authored together Ke‐Neng Chen links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 104 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Hit paper breakdown →
2023693
2
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Hit paper breakdown →
2017424
3
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
Hit paper breakdown →
2024233
4 2019212
5 2020205
6 2012175
7
Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Hit paper breakdown →
2021141
8
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Hit paper breakdown →
2024137
9 2018119
10 201991
11 200586
12 200282
13 201776
14 202164
15 201859
16 202359
17 201858
18 201452
19 201247
20 201646

About Ke‐Neng Chen

Ke‐Neng Chen is a scholar working on Neurology, Pulmonary and Respiratory Medicine, Oncology, Surgery and Cancer Research, having authored 104 papers that have together received 4.1k indexed citations. Recurring topics across this work include Myasthenia Gravis and Thymoma (23 papers), Lung Cancer Treatments and Mutations (20 papers), Esophageal Cancer Research and Treatment (20 papers), Lung Cancer Diagnosis and Treatment (15 papers), Lung Cancer Research Studies (8 papers), Gastric Cancer Management and Outcomes (8 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Cancer Genomics and Diagnostics (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.9k citations), Oncology (1.2k citations), Cancer Research (458 citations), Neurology (368 citations) and Surgery (641 citations). Ke‐Neng Chen has collaborated with scholars based in China, Ethiopia and United States. Frequent co-authors include Jonathan David Spicer, Moïshe Liberman, Jing Liang Yang, Heather A. Wakelee, Masahiro Tsuboi, Gastón Lucas Martinengo, Shugeng Gao, Jamie E. Chaft, Christophe Dooms and Ayman Samkari. Their work appears in journals such as Translational Lung Cancer Research, Journal of Clinical Oncology, Journal of Thoracic Oncology, The Annals of Thoracic Surgery and Diseases of the Esophagus.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact